CINRYZE is the first and only therapy indicated in the U.S. to help prevent angioedema attacks in pediatric patients with…
New facility will add 30% capacity to Shire’s internal plasma manufacturing network once fully operational Expanded capacity supports continued strong…
Clinical and real-world insights on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and the management of chronic hypoparathyroidism to be presented…
DUBLIN, 16-Jan-2018 — /EuropaWire/ — At Shire, we’ve been committed to the hemophilia community and the lives of every patient afflicted…
Marketing Authorization will enable patient access to ADYNOVI throughout Europe ZUG, 16-Jan-2018 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG),…
Mydayis, which is now available in the U.S., demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or…
Lifitegrast, if approved, would be the first and only new class treatment to address the signs and symptoms of dry eye…
Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD Lexington, M.A., 18-May-2017 — /EuropaWire/ — Shire plc…
https://youtu.be/sx11gbYMRFs Spoken word performer communicates plight of adults with ADHD who remain overlooked and unsupported. ZUG, 25-Oct-2016 — /EuropaWire/ — To…
Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection…
Integration on track; operating cost synergy expectations increased Pipeline progression continues with FDA approval of XIIDRA for dry eye disease…